PD L1 News and Research

RSS
Immune checkpoint protein may be a promising new target for prostate cancer immunotherapy

Immune checkpoint protein may be a promising new target for prostate cancer immunotherapy

Two new studies show how to enhance effectiveness of cancer immunotherapy

Two new studies show how to enhance effectiveness of cancer immunotherapy

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

Black NSCLC patients receiving immunotherapy have lower risk of death than white counterparts

Black NSCLC patients receiving immunotherapy have lower risk of death than white counterparts

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

Classic antidepressants show potential to enhance modern cancer treatments

Classic antidepressants show potential to enhance modern cancer treatments

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Penn Medicine and Wistar secure $11.7 million SPORE grant for three melanoma research projects

Penn Medicine and Wistar secure $11.7 million SPORE grant for three melanoma research projects

Specially designed lipid nanoparticles overcome resistance to anti-tumor immunotherapy

Specially designed lipid nanoparticles overcome resistance to anti-tumor immunotherapy

Scientists identify new approach to overcome resistance to cancer immunotherapy

Scientists identify new approach to overcome resistance to cancer immunotherapy

Synthetic molecular code shows promise towards improving immunotherapy response of cancer patients

Synthetic molecular code shows promise towards improving immunotherapy response of cancer patients

Study identifies actionable genes and candidate drugs in biliary tract cancer using a knowledgebase

Study identifies actionable genes and candidate drugs in biliary tract cancer using a knowledgebase

MSK researchers identify potential biomarker of response to checkpoint immunotherapy

MSK researchers identify potential biomarker of response to checkpoint immunotherapy

New PULSAR radiation-therapy strategy achieves better tumor control

New PULSAR radiation-therapy strategy achieves better tumor control

New prediction model can identify NSCLC patients who are not likely to respond to immunotherapy

New prediction model can identify NSCLC patients who are not likely to respond to immunotherapy

Prior treatment may impact efficacy of ACT-TIL in patients with metastatic melanoma

Prior treatment may impact efficacy of ACT-TIL in patients with metastatic melanoma

Nanotechnology may help improve treatment for colorectal cancer and melanoma

Nanotechnology may help improve treatment for colorectal cancer and melanoma

New immunotherapy strategy can eliminate pancreatic tumors in mice

New immunotherapy strategy can eliminate pancreatic tumors in mice

Using circulating tumor DNA to detect urothelial cancer relapse could help improve treatment

Using circulating tumor DNA to detect urothelial cancer relapse could help improve treatment

Researchers develop the most comprehensive molecular map of lung squamous cell carcinoma

Researchers develop the most comprehensive molecular map of lung squamous cell carcinoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.